After analyzing the options trading activity for Eli Lilly and Co (NYSE: LLY) on March 11, 2024, some interesting trends have emerged. Let’s take a closer look:
—
Investor Sentiment: Out of 128 trades reviewed, it was found that approximately 30% of investors had a bullish outlook, while around 69% took a bearish stance.
Options Breakdown: The trades analyzed included 44 puts totaling $2,883,996 and 84 calls totaling $6,058,304.
Price Targets: Major investors seem to have set their sights on a price range for Eli Lilly and Co between $390.0 and $1080.0 in the past three months.
Volume & Open Interest: The average open interest for options stands at 414.68 with a total volume of 11,046.00. Notably, there has been significant activity in high-value trades within the strike price range of $390.0 to $1080.0 over the last 30 days.
—
Specific options trades have also been identified in the last month for Eli Lilly and Co, including:
– A neutral call trade expiring on 08/16/24 at a strike price of $770.00 with a total trade price of $549.0K.
– Several bearish call trades expiring on different dates with varying strike prices and trade prices.
– A bullish call trade expiring on 06/21/24 at a strike price of $600.00 with a total trade price of $148.0K.
—
Eli Lilly is a pharmaceutical company known for its focus on neuroscience, cardiometabolic, cancer, and immunology products, such as Verzenio for cancer.
Eli Lilly and Company (LLY) Stock Update: March 11, 2024 – Strong Performance Despite Minor Decline
On March 11, 2024, Eli Lilly and Company (LLY) experienced a slight decrease in its stock price, closing at $734.37. This represents a drop of 3.64% or $27.77 since the previous market close. Despite this decline, LLY is still trading near the top of its 52-week range and above its 200-day simple moving average, indicating strong performance over a longer period.
After the market closed, LLY saw a small uptick in its stock price, rising by $0.03 in after-hours trading. While this increase is modest, it suggests that there may be some positive momentum building for the stock.
Investors in LLY should keep an eye on how the stock performs in the coming days to see if this slight uptick continues or if the stock experiences further fluctuations. It is also important to consider any external factors that may impact LLY’s stock price, such as industry news, economic indicators, or company announcements.
Overall, despite the drop in price on March 11, 2024, LLY’s strong performance relative to its 52-week range and moving average indicates that the stock may still be a solid investment option for those looking for stability and potential growth in the pharmaceutical sector.
Eli Lilly and Company (LLY) Stock Performance Analysis: Mixed Results on March 11, 2024
On March 11, 2024, Eli Lilly and Company (LLY) stock experienced mixed performances based on the latest financial data. The pharmaceutical giant reported a total revenue of $34.12 billion for the past year, representing a 19.56% increase compared to the previous year. However, the total revenue remained flat at $9.35 billion for the last quarter. In terms of net income, Eli Lilly reported a net income of $5.24 billion for the past year, which is a 16.08% decrease from the previous year. However, the net income saw a significant increase of 3914.63% to $2.19 billion for the last quarter. Earnings per share (EPS) for Eli Lilly stood at $5.80 for the past year, reflecting a 15.96% decrease from the previous year. The EPS remained flat at $2.31 for the last quarter. Overall, Eli Lilly’s financial performance on March 11, 2024, showed a mixed bag of results. While the total revenue saw a healthy increase compared to the previous year, the net income experienced a decline on an annual basis but a significant increase on a quarterly basis. The EPS remained relatively stable over the same periods. Investors and analysts may interpret these financial results differently and may have varying opinions on the future outlook for Eli Lilly stock. It is essential for investors to conduct thorough research and analysis before making any investment decisions based on these financial metrics.
